The Benefit of Adding Fish Oil to the Nutrition of Critically Ill Patients

This study has been completed.
Sponsor:
Collaborator:
Fresenius AG
Information provided by:
University Medicine Greifswald
ClinicalTrials.gov Identifier:
NCT00142220
First received: August 31, 2005
Last updated: September 8, 2006
Last verified: September 2006
  Purpose

We study whether an increased proportion of omega-3-fatty acids (contained in fish oil) in the nutrition of critically ill patients reduces systemic inflammation.


Condition Intervention Phase
Sepsis Syndrome
Drug: Defined percentage of omega-3-fatty acids
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Comparison Between Two Different Proportions of Omega-3- and Omega-6-Fatty Acids in the Parenteral Nutrition of Critically Ill Patients

Resource links provided by NLM:


Further study details as provided by University Medicine Greifswald:

Primary Outcome Measures:
  • level of IL-6 in serum
  • HLA-expression on monocytes

Secondary Outcome Measures:
  • number of nosocomial infections
  • days on mechanical ventilation
  • duration of ICU stay
  • mortality
  • SOFA score

Estimated Enrollment: 160
Study Start Date: January 2004
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • indication for parenteral nutrition

Exclusion Criteria:

  • hypertriglyceridemia
  • coagulation disorder
  • decompensated liver cirrhosis or acute liver failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00142220

Locations
Germany
Internistische ITS
Greifswald, Germany, 17475
Sponsors and Collaborators
University Medicine Greifswald
Fresenius AG
Investigators
Principal Investigator: Sigrun Friesecke, Dr. University Medicine Greifswald
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00142220     History of Changes
Other Study ID Numbers: OMEGAVEN
Study First Received: August 31, 2005
Last Updated: September 8, 2006
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Critical Illness
Toxemia
Sepsis
Systemic Inflammatory Response Syndrome
Disease Attributes
Pathologic Processes
Infection
Inflammation
Shock

ClinicalTrials.gov processed this record on October 19, 2014